NCT05243901

Brief Summary

Epipage 2 (Epidemiological study on small gestational ages) is a prospective population-based national cohort implemented to better understand the short, mid and long term future of premature children. This study was launched on 28 March 2011 by the researchers of the EPOPé team (Perinatal, Obstetric and Pediatric Epidemiology Research) of the Epidemiology and Biostatistics Research Centre (INSERM U1153), in collaboration with the Inserm 1027 Unit (Epidemiology and Analysis in Public Health: risks, chronic diseases and handicaps) and medical teams of public health and research in 25 French regions. The study focuses on children born before 35 weeks of amenorrhea. 3 follow-up steps for children included in the cohort have already been completed at 1, 2 and 5 and a half years of age. Currently, nearly 4,000 children are still eligible for follow-up. Since the children are 9 years old, the follow-up steps are shared with those set up in another birth cohort, the Elfe cohort (Étude Longitudinale Française depuis l'Enfance, (www.elfe-france.fr) ), as part of the RE-CO-NAI project. The RE-CO-NAI project is a research platform on cohorts of children followed since birth in order to be able to study in a global and multidisciplinary way the major issues of the health, development and socialization of children. This RE-CO-NAI project was funded by the EQUIPEX 2011 call for projects as part of future investments. This protocol, which is part of the RECONAI project, concerns the fully shared follow-up phase, proposed in the 10th year for the children of the two cohorts.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,383

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 2, 2022

Completed
15 days until next milestone

First Posted

Study publicly available on registry

February 17, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

February 17, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 21, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 21, 2022

Completed
Last Updated

May 16, 2025

Status Verified

March 1, 2025

Enrollment Period

10 months

First QC Date

February 2, 2022

Last Update Submit

May 13, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • Relationships between prematurity, early growth and cardiometabolic disorders

    Different cardiometabolic parameters will be studied (90th percentile waist for age and sex, 90th percentile systolic or diastolic pressure for age and sex)

    10 years and a half

  • Relationship between parenting educational skills and children's quality of life

    VSPA scale (Adolescent Experience and Perceived Health)

    10 years and a half

  • Factors influencing children's puberty development

    Tanner stage

    10 years and a half

  • Factors influencing the child's fitness and motor skills

    Children's Endurance and Motor Ability Test Results upper or equal to 75th percentile of distribution for sex

    10 years and a half

Eligibility Criteria

Age10 Years - 11 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Children born before 35 weeks of amenorrhea still eligible for follow-up at 10 years of age

You may qualify if:

  • Children initially included in the Epipage 2 study,
  • Not lost to follow up (i.e. having participated in at least one of the Epipage 2 surveys since the age of 1 year),
  • Neither parent has expressed a definitive refusal to participate in the follow-up study.

You may not qualify if:

  • Refusal of the investigation by one of the two parents or holders of parental authority,
  • Residence abroad

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

INSERM (National Institute of Health and Medical Research) - Université Paris Cité, INRAE, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé Team) Center for Epidemiology and Statistics

Paris, 74014, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 2, 2022

First Posted

February 17, 2022

Study Start

February 17, 2022

Primary Completion

December 21, 2022

Study Completion

December 21, 2022

Last Updated

May 16, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations